Baird analyst Michael Ulz added Karyopharm Therapeutics (NASDAQ: KPTI) as a Fresh Pick after hosting management for a series ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE